TTM
61.7%
YoY change
+2.69pp
Trough year (2007)
53.7%
Peak year (2000)
73.4%
Latest annual
59.4%
Gross Margin history chart for ResMed (RMD) from 1993 to 2025
Latest: 59.4%
Gross Margin change chart for ResMed (RMD) from 1993 to 2025
Latest: +2.69pp
Gross Margin history table for ResMed (RMD) from 1993 to 2025
| 2025 | 59.4% | +2.69pp | ||
| 2024 | 56.7% | +0.89pp | ||
| 2023 | 55.8% | -0.79pp | ||
| 2022 | 56.6% | -0.95pp | ||
| 2021 | 57.5% | -0.56pp | ||
| 2020 | 58.1% | -0.86pp | ||
| 2019 | 59.0% | +0.74pp | ||
| 2018 | 58.2% | +0.06pp | ||
| 2017 | 58.1% | +0.14pp | ||
| 2016 | 58.0% | -2.24pp | ||
| 2015 | 60.2% | -3.41pp | ||
| 2014 | 63.7% | +1.54pp | ||
| 2013 | 62.1% | +2.14pp | ||
| 2012 | 60.0% | +0.34pp | ||
| 2011 | 59.6% | -0.37pp | ||
| 2010 | 60.0% | -0.14pp | ||
| 2009 | 60.1% | +1.04pp | ||
| 2008 | 59.1% | +5.43pp | ||
| 2007 | 53.7% | -8.42pp | ||
| 2006 | 62.1% | -2.50pp | ||
| 2005 | 64.6% | +0.73pp | ||
| 2004 | 63.9% | +0.60pp | ||
| 2003 | 63.3% | -2.02pp | ||
| 2002 | 65.3% | -2.24pp | ||
| 2001 | 67.5% | -5.88pp | ||
| 2000 | 73.4% | +1.40pp | ||
| 1999 | 72.0% | +1.18pp | ||
| 1998 | 70.8% | +6.80pp | ||
| 1997 | 64.0% | +9.40pp | ||
| 1996 | 54.6% | +0.16pp | ||
| 1995 | 54.5% | -3.09pp | ||
| 1994 | 57.6% | -4.78pp | ||
| 1993 | 62.3% | — |
- 202559.4%+2.69pp
- 202456.7%+0.89pp
- 202355.8%-0.79pp
- 202256.6%-0.95pp
- 202157.5%-0.56pp
- 202058.1%-0.86pp
- 201959.0%+0.74pp
- 201858.2%+0.06pp
- 201758.1%+0.14pp
- 201658.0%-2.24pp
- 201560.2%-3.41pp
- 201463.7%+1.54pp
- 201362.1%+2.14pp
- 201260.0%+0.34pp
- 201159.6%-0.37pp
- 201060.0%-0.14pp
- 200960.1%+1.04pp
- 200859.1%+5.43pp
- 200753.7%-8.42pp
- 200662.1%-2.50pp
- 200564.6%+0.73pp
- 200463.9%+0.60pp
- 200363.3%-2.02pp
- 200265.3%-2.24pp
- 200167.5%-5.88pp
- 200073.4%+1.40pp
- 199972.0%+1.18pp
- 199870.8%+6.80pp
- 199764.0%+9.40pp
- 199654.6%+0.16pp
- 199554.5%-3.09pp
- 199457.6%-4.78pp
- 199362.3%—
Gross Margin values are taken from ResMed's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Gross Margin at ResMed (RMD)
According to ResMed's latest reported financial statements, the company's latest reported gross margin is 61.7%. Gross margin is gross profit divided by revenue, expressed as a percentage. It shows how much of each sales dollar survives the direct cost of goods sold — before operating expenses, interest, and taxes. A higher gross margin generally signals pricing power and production efficiency. Margins are most meaningful compared against sector peers and a company's own history.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, ResMed (RMD) gross margin totalled 59.36% – expanded 2.7 percentage points year-over-year.
2000 marks the peak gross margin at 73.41%, with the historical low of 53.68% recorded in 2007.
ResMed Gross Margin by Year
ResMed Gross Margin 2025: 59.4%
ResMed gross margin in 2025 was 59.36%, expanded 2.7 percentage points from 2024.
ResMed Gross Margin 2024: 56.7%
2024's gross margin for ResMed came in at 56.67%, expanded 0.9 percentage points from 2023.
ResMed Gross Margin 2023: 55.8%
ResMed posted gross margin of 55.78% in 2023, contracted 0.8 percentage points from 2022.
ResMed Gross Margin 2022: 56.6%
In 2022, ResMed reported gross margin of 56.57%, contracted 1.0 percentage points from 2021.
ResMed Gross Margin 2021: 57.5%
ResMed gross margin in 2021 was 57.53%.
See more financial history for ResMed (RMD).
Sector peers by Gross Margin
Healthcare peers of ResMed (RMD), ranked by their latest gross margin
| 83.5% | |
| 81.8% | |
| 81.7% | |
| 75.9% | |
| 71.5% | |
| 70.7% | |
| 70.0% | |
| 18.8% |
- 83.5%
- 81.8%
- 81.7%
- 75.9%
- 71.5%
- 70.7%
Frequently asked questions
ResMed (RMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation